Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) - Stock analysts at Wedbush issued their Q2 2025 earnings per share (EPS) estimates for Maze Therapeutics in a report released on Tuesday, July 8th. Wedbush analyst L. Chico expects that the company will earn ($0.77) per share for the quarter. Wedbush has a "Outperform" rating and a $17.00 price objective on the stock. Wedbush also issued estimates for Maze Therapeutics' Q3 2025 earnings at ($0.78) EPS, Q4 2025 earnings at ($0.79) EPS, FY2025 earnings at ($3.39) EPS, Q1 2026 earnings at ($0.81) EPS, Q2 2026 earnings at ($0.68) EPS, Q3 2026 earnings at ($0.69) EPS, Q4 2026 earnings at ($0.70) EPS, FY2026 earnings at ($2.86) EPS, FY2027 earnings at ($2.65) EPS, FY2028 earnings at ($2.71) EPS and FY2029 earnings at ($2.84) EPS.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.39).
Separately, Guggenheim reiterated a "buy" rating and set a $19.00 price objective on shares of Maze Therapeutics in a report on Wednesday, April 2nd. Four analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Maze Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $23.50.
Get Our Latest Stock Analysis on Maze Therapeutics
Maze Therapeutics Price Performance
Shares of Maze Therapeutics stock traded down $0.59 during trading hours on Thursday, hitting $15.05. The company's stock had a trading volume of 127,024 shares, compared to its average volume of 118,689. Maze Therapeutics has a 12 month low of $6.71 and a 12 month high of $17.00. The stock has a 50 day simple moving average of $11.65.
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the stock. Goldman Sachs Group Inc. acquired a new stake in shares of Maze Therapeutics in the first quarter valued at approximately $145,000. Rhumbline Advisers bought a new stake in shares of Maze Therapeutics during the 1st quarter valued at $80,000. Woodline Partners LP bought a new stake in shares of Maze Therapeutics during the 1st quarter valued at $10,229,000. Octagon Capital Advisors LP acquired a new position in shares of Maze Therapeutics during the 1st quarter worth $5,153,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Maze Therapeutics during the 1st quarter worth $57,000.
About Maze Therapeutics
(
Get Free Report)
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
Featured Articles
Before you consider Maze Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maze Therapeutics wasn't on the list.
While Maze Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
